aluates Reports

$ 0.0

Automative

Global Biologics for Tumors Market Research Report 2025

Published Date: November 2025

Report Code: QYRE-Auto-30B19750

BUY CHAPTERS

Global Biologics for Tumors Market Research Report 2025

Code: QYRE-Auto-30B19750

Report

November 2025

Pages:124

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

Biologics for Tumors Market Size

The global market for Biologics for Tumors was valued at US$ 184950 million in the year 2024 and is projected to reach a revised size of US$ 348870 million by 2031, growing at a CAGR of 10.1% during the forecast period.

Biologics for Tumors Market

In the pharmaceutical field, biomanufacturing refers to the use of living biological systems (such as mammalian, microbial, or plant cells) as "production factories" to transform complex biomolecules into drugs for the treatment or prevention of diseases through precisely controlled cultivation, fermentation, isolation, and purification processes. This process differs from traditional chemical synthesis in that it emphasizes the correct folding, modification, and biological activity of macromolecules such as proteins and nucleic acids. It also requires strict adherence to regulatory standards such as cGMP to ensure product safety, efficacy, and batch consistency. Typical products include monoclonal antibodies, recombinant proteins, vaccines, and gene or cell therapy formulations, reflecting the shift in modern pharmaceutical manufacturing from chemical manufacturing to bio-driven innovation.

Oncology research focuses on tumors, which form due to abnormal cell growth in the body. Benign tumors are relatively mild, while malignant tumors, such as breast, lung, colorectal, and prostate cancers, are capable of invasion and metastasis. The emergence of biologic drugs has profoundly transformed the cancer treatment landscape. From monoclonal antibodies targeting HER2, such as trastuzumab, to immune checkpoint inhibitors such as anti-PD-1 antibodies, they have significantly prolonged patient survival. The latest explorations are moving towards more personalized and diversified approaches: bispecific antibodies, antibody-drug conjugates (ADCs), and cell therapies such as CAR-T continue to achieve breakthroughs in clinical efficacy, while personalized cancer vaccines are also rapidly advancing. Advances in biomanufacturing have made complex and sophisticated cancer treatments a reality.

Biologics (pharmaceuticals) in the oncology field include monoclonal antibodies, antibody-drug conjugates (ADCs), CAR-T drugs, and recombinant protein drugs. Representative drugs include Keytruda (sales of US$29,482 million in 2024), Dupixent (sales of US$14,141 million in 2024), Skyrizi (sales of US$11,718 million in 2024), DARZALEX (sales of US$11,670 million in 2024), and Opdivo (sales of US$9,304 million in 2024). All of these drugs boast gross profit margins exceeding 70%.

In recent years, the pharmaceutical industry's R&D focus has shifted from solely focusing on the discovery and optimization of small molecule drugs. Driven by biomanufacturing, the product portfolio has evolved into a multimodal, biology-centric landscape. While traditional proteins and monoclonal antibodies remain the bulk of the market, manufacturing processes are constantly being optimized to improve yield and quality consistency. Meanwhile, emerging therapeutic modalities such as cell and gene therapies, mRNA, nucleic acid therapies, and gene editing-related products are placing new demands on biomanufacturing. Upstream cell line development, expression system optimization, vector production, sterile and pyrogen-free downstream purification, and process stability for both in vitro and in vivo delivery systems have all become key R&D priorities. Consequently, the boundaries between R&D and manufacturing are becoming increasingly blurred: early-stage molecular design must consider manufacturability for scalable production, while process development, in turn, influences clinical dosing regimens and development cadence. With the maturity of AI/data-driven design, synthetic biology, and high-throughput screening technologies, the path from early target identification to producible biologics has been significantly shortened. This, in turn, requires manufacturing teams to engage earlier in early drug development to ensure that candidate molecules do not encounter unresolvable process bottlenecks when entering mid- to late-stage large-scale production. As a result, R&D trends are showing a significant shift from single-molecule innovation to molecule-process co-design. This trend will continue to intensify, driving companies to adjust their R&D organizational structures and investment allocations to balance scientific innovation with production feasibility.

The pharmaceutical oncology landscape today is significantly different than it was a decade ago. As the fastest-growing and most active segment in drug development, breakthroughs in science and technology have driven progress in oncology, deepening researchers' understanding of cancer biology, immunology, and genetics. This evolving body of knowledge has also facilitated the development of new treatment strategies, expanding treatment options and improving patient outcomes. Many patient populations previously treated with non-selective chemotherapy are now receiving targeted drugs and cancer immunotherapies tailored to the molecular mechanisms and clinical characteristics of their disease. For biopharmaceutical companies, oncology represents a highly attractive market.

This report aims to provide a comprehensive presentation of the global market for Biologics for Tumors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biologics for Tumors.

The Biologics for Tumors market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biologics for Tumors market comprehensively. Regional market sizes, concerning products by Type, by Application, by Properties and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Biologics for Tumors companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Biologics for Tumors Market Report

Report Metric	Details
Report Name	Biologics for Tumors Market
Accounted market size in year	US$ 184950 million
Forecasted market size in 2031	US$ 348870 million
CAGR	10.1%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Monoclonal Antibodies Recombinant Protein Drugs Antibody-Drug Conjugates (ADCs) Enzyme Replacement Therapy CAR-T Drugs Small Nucleic Acid Drugs Others
Segment by Properties	Biopharmaceuticals Biosimilars
Segment by Application	Lymphoma Myeloma Colorectal Renal Cell Carcinoma Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Merck, Novo Nordisk, Sanofi, Johnson & Johnson, AbbVie, Amgen, AstraZeneca, Takeda Pharmaceuticals, Bristol-Myers Squib, Pfizer, Eli Lilly, Novartis, GSK, CSL Limited, Regeneron Pharmaceuticals, Kexing Biopharm, Biogen, GileadSciences, Shanghai Junshi Biosciences, Sarepta Therapeutics, Inc., Changchun High-Tech Industry, Sino Biopharmaceutical Limited, 3SBio Inc., CARsgen, Innovent Biologics, Qilu Pharmaceutical, Boehringer Ingelheim, BeiGene, Jiangsu Hengrui Pharmaceuticals, Alphamab Oncology, Shanghai Henlius Biotech, Ionis Pharmaceuticals, Gan & Lee Pharmaceuticals, Anhui Anke Biotechnology
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, by Properties etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biologics for Tumors company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Biologics for Tumors Market growing?

Ans: The Biologics for Tumors Market witnessing a CAGR of 10.1% during the forecast period 2025-2031.

What is the Biologics for Tumors Market size in 2031?

Ans: The Biologics for Tumors Market size in 2031 will be US$ 348870 million.

Who are the main players in the Biologics for Tumors Market report?

Ans: The main players in the Biologics for Tumors Market are Roche, Merck, Novo Nordisk, Sanofi, Johnson & Johnson, AbbVie, Amgen, AstraZeneca, Takeda Pharmaceuticals, Bristol-Myers Squib, Pfizer, Eli Lilly, Novartis, GSK, CSL Limited, Regeneron Pharmaceuticals, Kexing Biopharm, Biogen, GileadSciences, Shanghai Junshi Biosciences, Sarepta Therapeutics, Inc., Changchun High-Tech Industry, Sino Biopharmaceutical Limited, 3SBio Inc., CARsgen, Innovent Biologics, Qilu Pharmaceutical, Boehringer Ingelheim, BeiGene, Jiangsu Hengrui Pharmaceuticals, Alphamab Oncology, Shanghai Henlius Biotech, Ionis Pharmaceuticals, Gan & Lee Pharmaceuticals, Anhui Anke Biotechnology

What are the Application segmentation covered in the Biologics for Tumors Market report?

Ans: The Applications covered in the Biologics for Tumors Market report are Lymphoma, Myeloma, Colorectal, Renal Cell Carcinoma, Others

What are the Type segmentation covered in the Biologics for Tumors Market report?

Ans: The Types covered in the Biologics for Tumors Market report are Monoclonal Antibodies, Recombinant Protein Drugs, Antibody-Drug Conjugates (ADCs), Enzyme Replacement Therapy, CAR-T Drugs, Small Nucleic Acid Drugs, Others

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Biologics for Tumors Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Monoclonal Antibodies

1.2.3 Recombinant Protein Drugs

1.2.4 Antibody-Drug Conjugates (ADCs)

1.2.5 Enzyme Replacement Therapy

1.2.6 CAR-T Drugs

1.2.7 Small Nucleic Acid Drugs

1.2.8 Others

1.3 Market by Properties

1.3.1 Global Biologics for Tumors Market Size Growth Rate by Properties: 2020 VS 2024 VS 2031

1.3.2 Biopharmaceuticals

1.3.3 Biosimilars

1.4 Market by Application

1.4.1 Global Biologics for Tumors Market Growth by Application: 2020 VS 2024 VS 2031

1.4.2 Lymphoma

1.4.3 Myeloma

1.4.4 Colorectal

1.4.5 Renal Cell Carcinoma

1.4.6 Others

1.5 Assumptions and Limitations

1.6 Study Objectives

1.7 Years Considered

2 Global Growth Trends

2.1 Global Biologics for Tumors Market Perspective (2020-2031)

2.2 Global Biologics for Tumors Growth Trends by Region

2.2.1 Global Biologics for Tumors Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Biologics for Tumors Historic Market Size by Region (2020-2025)

2.2.3 Biologics for Tumors Forecasted Market Size by Region (2026-2031)

2.3 Biologics for Tumors Market Dynamics

2.3.1 Biologics for Tumors Industry Trends

2.3.2 Biologics for Tumors Market Drivers

2.3.3 Biologics for Tumors Market Challenges

2.3.4 Biologics for Tumors Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Biologics for Tumors Players by Revenue

3.1.1 Global Top Biologics for Tumors Players by Revenue (2020-2025)

3.1.2 Global Biologics for Tumors Revenue Market Share by Players (2020-2025)

3.2 Global Top Biologics for Tumors Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Biologics for Tumors Revenue

3.4 Global Biologics for Tumors Market Concentration Ratio

3.4.1 Global Biologics for Tumors Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Biologics for Tumors Revenue in 2024

3.5 Global Key Players of Biologics for Tumors Head office and Area Served

3.6 Global Key Players of Biologics for Tumors, Product and Application

3.7 Global Key Players of Biologics for Tumors, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Biologics for Tumors Breakdown Data by Type

4.1 Global Biologics for Tumors Historic Market Size by Type (2020-2025)

4.2 Global Biologics for Tumors Forecasted Market Size by Type (2026-2031)

5 Biologics for Tumors Breakdown Data by Application

5.1 Global Biologics for Tumors Historic Market Size by Application (2020-2025)

5.2 Global Biologics for Tumors Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Biologics for Tumors Market Size (2020-2031)

6.2 North America Biologics for Tumors Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Biologics for Tumors Market Size by Country (2020-2025)

6.4 North America Biologics for Tumors Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Biologics for Tumors Market Size (2020-2031)

7.2 Europe Biologics for Tumors Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Biologics for Tumors Market Size by Country (2020-2025)

7.4 Europe Biologics for Tumors Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Biologics for Tumors Market Size (2020-2031)

8.2 Asia-Pacific Biologics for Tumors Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Biologics for Tumors Market Size by Region (2020-2025)

8.4 Asia-Pacific Biologics for Tumors Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Biologics for Tumors Market Size (2020-2031)

9.2 Latin America Biologics for Tumors Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Biologics for Tumors Market Size by Country (2020-2025)

9.4 Latin America Biologics for Tumors Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Biologics for Tumors Market Size (2020-2031)

10.2 Middle East & Africa Biologics for Tumors Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Biologics for Tumors Market Size by Country (2020-2025)

10.4 Middle East & Africa Biologics for Tumors Market Size by Country (2026-2031)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Roche

11.1.1 Roche Company Details

11.1.2 Roche Business Overview

11.1.3 Roche Biologics for Tumors Introduction

11.1.4 Roche Revenue in Biologics for Tumors Business (2020-2025)

11.1.5 Roche Recent Development

11.2 Merck

11.2.1 Merck Company Details

11.2.2 Merck Business Overview

11.2.3 Merck Biologics for Tumors Introduction

11.2.4 Merck Revenue in Biologics for Tumors Business (2020-2025)

11.2.5 Merck Recent Development

11.3 Novo Nordisk

11.3.1 Novo Nordisk Company Details

11.3.2 Novo Nordisk Business Overview

11.3.3 Novo Nordisk Biologics for Tumors Introduction

11.3.4 Novo Nordisk Revenue in Biologics for Tumors Business (2020-2025)

11.3.5 Novo Nordisk Recent Development

11.4 Sanofi

11.4.1 Sanofi Company Details

11.4.2 Sanofi Business Overview

11.4.3 Sanofi Biologics for Tumors Introduction

11.4.4 Sanofi Revenue in Biologics for Tumors Business (2020-2025)

11.4.5 Sanofi Recent Development

11.5 Johnson & Johnson

11.5.1 Johnson & Johnson Company Details

11.5.2 Johnson & Johnson Business Overview

11.5.3 Johnson & Johnson Biologics for Tumors Introduction

11.5.4 Johnson & Johnson Revenue in Biologics for Tumors Business (2020-2025)

11.5.5 Johnson & Johnson Recent Development

11.6 AbbVie

11.6.1 AbbVie Company Details

11.6.2 AbbVie Business Overview

11.6.3 AbbVie Biologics for Tumors Introduction

11.6.4 AbbVie Revenue in Biologics for Tumors Business (2020-2025)

11.6.5 AbbVie Recent Development

11.7 Amgen

11.7.1 Amgen Company Details

11.7.2 Amgen Business Overview

11.7.3 Amgen Biologics for Tumors Introduction

11.7.4 Amgen Revenue in Biologics for Tumors Business (2020-2025)

11.7.5 Amgen Recent Development

11.8 AstraZeneca

11.8.1 AstraZeneca Company Details

11.8.2 AstraZeneca Business Overview

11.8.3 AstraZeneca Biologics for Tumors Introduction

11.8.4 AstraZeneca Revenue in Biologics for Tumors Business (2020-2025)

11.8.5 AstraZeneca Recent Development

11.9 Takeda Pharmaceuticals

11.9.1 Takeda Pharmaceuticals Company Details

11.9.2 Takeda Pharmaceuticals Business Overview

11.9.3 Takeda Pharmaceuticals Biologics for Tumors Introduction

11.9.4 Takeda Pharmaceuticals Revenue in Biologics for Tumors Business (2020-2025)

11.9.5 Takeda Pharmaceuticals Recent Development

11.10 Bristol-Myers Squib

11.10.1 Bristol-Myers Squib Company Details

11.10.2 Bristol-Myers Squib Business Overview

11.10.3 Bristol-Myers Squib Biologics for Tumors Introduction

11.10.4 Bristol-Myers Squib Revenue in Biologics for Tumors Business (2020-2025)

11.10.5 Bristol-Myers Squib Recent Development

11.11 Pfizer

11.11.1 Pfizer Company Details

11.11.2 Pfizer Business Overview

11.11.3 Pfizer Biologics for Tumors Introduction

11.11.4 Pfizer Revenue in Biologics for Tumors Business (2020-2025)

11.11.5 Pfizer Recent Development

11.12 Eli Lilly

11.12.1 Eli Lilly Company Details

11.12.2 Eli Lilly Business Overview

11.12.3 Eli Lilly Biologics for Tumors Introduction

11.12.4 Eli Lilly Revenue in Biologics for Tumors Business (2020-2025)

11.12.5 Eli Lilly Recent Development

11.13 Novartis

11.13.1 Novartis Company Details

11.13.2 Novartis Business Overview

11.13.3 Novartis Biologics for Tumors Introduction

11.13.4 Novartis Revenue in Biologics for Tumors Business (2020-2025)

11.13.5 Novartis Recent Development

11.14 GSK

11.14.1 GSK Company Details

11.14.2 GSK Business Overview

11.14.3 GSK Biologics for Tumors Introduction

11.14.4 GSK Revenue in Biologics for Tumors Business (2020-2025)

11.14.5 GSK Recent Development

11.15 CSL Limited

11.15.1 CSL Limited Company Details

11.15.2 CSL Limited Business Overview

11.15.3 CSL Limited Biologics for Tumors Introduction

11.15.4 CSL Limited Revenue in Biologics for Tumors Business (2020-2025)

11.15.5 CSL Limited Recent Development

11.16 Regeneron Pharmaceuticals

11.16.1 Regeneron Pharmaceuticals Company Details

11.16.2 Regeneron Pharmaceuticals Business Overview

11.16.3 Regeneron Pharmaceuticals Biologics for Tumors Introduction

11.16.4 Regeneron Pharmaceuticals Revenue in Biologics for Tumors Business (2020-2025)

11.16.5 Regeneron Pharmaceuticals Recent Development

11.17 Kexing Biopharm

11.17.1 Kexing Biopharm Company Details

11.17.2 Kexing Biopharm Business Overview

11.17.3 Kexing Biopharm Biologics for Tumors Introduction

11.17.4 Kexing Biopharm Revenue in Biologics for Tumors Business (2020-2025)

11.17.5 Kexing Biopharm Recent Development

11.18 Biogen

11.18.1 Biogen Company Details

11.18.2 Biogen Business Overview

11.18.3 Biogen Biologics for Tumors Introduction

11.18.4 Biogen Revenue in Biologics for Tumors Business (2020-2025)

11.18.5 Biogen Recent Development

11.19 GileadSciences

11.19.1 GileadSciences Company Details

11.19.2 GileadSciences Business Overview

11.19.3 GileadSciences Biologics for Tumors Introduction

11.19.4 GileadSciences Revenue in Biologics for Tumors Business (2020-2025)

11.19.5 GileadSciences Recent Development

11.20 Shanghai Junshi Biosciences

11.20.1 Shanghai Junshi Biosciences Company Details

11.20.2 Shanghai Junshi Biosciences Business Overview

11.20.3 Shanghai Junshi Biosciences Biologics for Tumors Introduction

11.20.4 Shanghai Junshi Biosciences Revenue in Biologics for Tumors Business (2020-2025)

11.20.5 Shanghai Junshi Biosciences Recent Development

11.21 Sarepta Therapeutics, Inc.

11.21.1 Sarepta Therapeutics, Inc. Company Details

11.21.2 Sarepta Therapeutics, Inc. Business Overview

11.21.3 Sarepta Therapeutics, Inc. Biologics for Tumors Introduction

11.21.4 Sarepta Therapeutics, Inc. Revenue in Biologics for Tumors Business (2020-2025)

11.21.5 Sarepta Therapeutics, Inc. Recent Development

11.22 Changchun High-Tech Industry

11.22.1 Changchun High-Tech Industry Company Details

11.22.2 Changchun High-Tech Industry Business Overview

11.22.3 Changchun High-Tech Industry Biologics for Tumors Introduction

11.22.4 Changchun High-Tech Industry Revenue in Biologics for Tumors Business (2020-2025)

11.22.5 Changchun High-Tech Industry Recent Development

11.23 Sino Biopharmaceutical Limited

11.23.1 Sino Biopharmaceutical Limited Company Details

11.23.2 Sino Biopharmaceutical Limited Business Overview

11.23.3 Sino Biopharmaceutical Limited Biologics for Tumors Introduction

11.23.4 Sino Biopharmaceutical Limited Revenue in Biologics for Tumors Business (2020-2025)

11.23.5 Sino Biopharmaceutical Limited Recent Development

11.24 Kexing Biopharm

11.24.1 Kexing Biopharm Company Details

11.24.2 Kexing Biopharm Business Overview

11.24.3 Kexing Biopharm Biologics for Tumors Introduction

11.24.4 Kexing Biopharm Revenue in Biologics for Tumors Business (2020-2025)

11.24.5 Kexing Biopharm Recent Development

11.25 3SBio Inc.

11.25.1 3SBio Inc. Company Details

11.25.2 3SBio Inc. Business Overview

11.25.3 3SBio Inc. Biologics for Tumors Introduction

11.25.4 3SBio Inc. Revenue in Biologics for Tumors Business (2020-2025)

11.25.5 3SBio Inc. Recent Development

11.26 CARsgen

11.26.1 CARsgen Company Details

11.26.2 CARsgen Business Overview

11.26.3 CARsgen Biologics for Tumors Introduction

11.26.4 CARsgen Revenue in Biologics for Tumors Business (2020-2025)

11.26.5 CARsgen Recent Development

11.27 Innovent Biologics

11.27.1 Innovent Biologics Company Details

11.27.2 Innovent Biologics Business Overview

11.27.3 Innovent Biologics Biologics for Tumors Introduction

11.27.4 Innovent Biologics Revenue in Biologics for Tumors Business (2020-2025)

11.27.5 Innovent Biologics Recent Development

11.28 Qilu Pharmaceutical

11.28.1 Qilu Pharmaceutical Company Details

11.28.2 Qilu Pharmaceutical Business Overview

11.28.3 Qilu Pharmaceutical Biologics for Tumors Introduction

11.28.4 Qilu Pharmaceutical Revenue in Biologics for Tumors Business (2020-2025)

11.28.5 Qilu Pharmaceutical Recent Development

11.29 Boehringer Ingelheim

11.29.1 Boehringer Ingelheim Company Details

11.29.2 Boehringer Ingelheim Business Overview

11.29.3 Boehringer Ingelheim Biologics for Tumors Introduction

11.29.4 Boehringer Ingelheim Revenue in Biologics for Tumors Business (2020-2025)

11.29.5 Boehringer Ingelheim Recent Development

11.30 BeiGene

11.30.1 BeiGene Company Details

11.30.2 BeiGene Business Overview

11.30.3 BeiGene Biologics for Tumors Introduction

11.30.4 BeiGene Revenue in Biologics for Tumors Business (2020-2025)

11.30.5 BeiGene Recent Development

11.31 Jiangsu Hengrui Pharmaceuticals

11.31.1 Jiangsu Hengrui Pharmaceuticals Company Details

11.31.2 Jiangsu Hengrui Pharmaceuticals Business Overview

11.31.3 Jiangsu Hengrui Pharmaceuticals Biologics for Tumors Introduction

11.31.4 Jiangsu Hengrui Pharmaceuticals Revenue in Biologics for Tumors Business (2020-2025)

11.31.5 Jiangsu Hengrui Pharmaceuticals Recent Development

11.32 Alphamab Oncology

11.32.1 Alphamab Oncology Company Details

11.32.2 Alphamab Oncology Business Overview

11.32.3 Alphamab Oncology Biologics for Tumors Introduction

11.32.4 Alphamab Oncology Revenue in Biologics for Tumors Business (2020-2025)

11.32.5 Alphamab Oncology Recent Development

11.33 Shanghai Henlius Biotech

11.33.1 Shanghai Henlius Biotech Company Details

11.33.2 Shanghai Henlius Biotech Business Overview

11.33.3 Shanghai Henlius Biotech Biologics for Tumors Introduction

11.33.4 Shanghai Henlius Biotech Revenue in Biologics for Tumors Business (2020-2025)

11.33.5 Shanghai Henlius Biotech Recent Development

11.34 Ionis Pharmaceuticals

11.34.1 Ionis Pharmaceuticals Company Details

11.34.2 Ionis Pharmaceuticals Business Overview

11.34.3 Ionis Pharmaceuticals Biologics for Tumors Introduction

11.34.4 Ionis Pharmaceuticals Revenue in Biologics for Tumors Business (2020-2025)

11.34.5 Ionis Pharmaceuticals Recent Development

11.35 Gan & Lee Pharmaceuticals

11.35.1 Gan & Lee Pharmaceuticals Company Details

11.35.2 Gan & Lee Pharmaceuticals Business Overview

11.35.3 Gan & Lee Pharmaceuticals Biologics for Tumors Introduction

11.35.4 Gan & Lee Pharmaceuticals Revenue in Biologics for Tumors Business (2020-2025)

11.35.5 Gan & Lee Pharmaceuticals Recent Development

11.36 Anhui Anke Biotechnology

11.36.1 Anhui Anke Biotechnology Company Details

11.36.2 Anhui Anke Biotechnology Business Overview

11.36.3 Anhui Anke Biotechnology Biologics for Tumors Introduction

11.36.4 Anhui Anke Biotechnology Revenue in Biologics for Tumors Business (2020-2025)

11.36.5 Anhui Anke Biotechnology Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

List of Tables

Table 1. Global Biologics for Tumors Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Monoclonal Antibodies

Table 3. Key Players of Recombinant Protein Drugs

Table 4. Key Players of Antibody-Drug Conjugates (ADCs)

Table 5. Key Players of Enzyme Replacement Therapy

Table 6. Key Players of CAR-T Drugs

Table 7. Key Players of Small Nucleic Acid Drugs

Table 8. Key Players of Others

Table 9. Global Biologics for Tumors Market Size Growth Rate by Properties (US$ Million): 2020 VS 2024 VS 2031

Table 10. Key Players of Biopharmaceuticals

Table 11. Key Players of Biosimilars

Table 12. Global Biologics for Tumors Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 13. Global Biologics for Tumors Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 14. Global Biologics for Tumors Market Size by Region (2020-2025) & (US$ Million)

Table 15. Global Biologics for Tumors Market Share by Region (2020-2025)

Table 16. Global Biologics for Tumors Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 17. Global Biologics for Tumors Market Share by Region (2026-2031)

Table 18. Biologics for Tumors Market Trends

Table 19. Biologics for Tumors Market Drivers

Table 20. Biologics for Tumors Market Challenges

Table 21. Biologics for Tumors Market Restraints

Table 22. Global Biologics for Tumors Revenue by Players (2020-2025) & (US$ Million)

Table 23. Global Biologics for Tumors Market Share by Players (2020-2025)

Table 24. Global Top Biologics for Tumors Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biologics for Tumors as of 2024)

Table 25. Ranking of Global Top Biologics for Tumors Companies by Revenue (US$ Million) in 2024

Table 26. Global 5 Largest Players Market Share by Biologics for Tumors Revenue (CR5 and HHI) & (2020-2025)

Table 27. Global Key Players of Biologics for Tumors, Headquarters and Area Served

Table 28. Global Key Players of Biologics for Tumors, Product and Application

Table 29. Global Key Players of Biologics for Tumors, Date of Enter into This Industry

Table 30. Mergers & Acquisitions, Expansion Plans

Table 31. Global Biologics for Tumors Market Size by Type (2020-2025) & (US$ Million)

Table 32. Global Biologics for Tumors Revenue Market Share by Type (2020-2025)

Table 33. Global Biologics for Tumors Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 34. Global Biologics for Tumors Revenue Market Share by Type (2026-2031)

Table 35. Global Biologics for Tumors Market Size by Application (2020-2025) & (US$ Million)

Table 36. Global Biologics for Tumors Revenue Market Share by Application (2020-2025)

Table 37. Global Biologics for Tumors Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 38. Global Biologics for Tumors Revenue Market Share by Application (2026-2031)

Table 39. North America Biologics for Tumors Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 40. North America Biologics for Tumors Market Size by Country (2020-2025) & (US$ Million)

Table 41. North America Biologics for Tumors Market Size by Country (2026-2031) & (US$ Million)

Table 42. Europe Biologics for Tumors Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 43. Europe Biologics for Tumors Market Size by Country (2020-2025) & (US$ Million)

Table 44. Europe Biologics for Tumors Market Size by Country (2026-2031) & (US$ Million)

Table 45. Asia-Pacific Biologics for Tumors Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 46. Asia-Pacific Biologics for Tumors Market Size by Region (2020-2025) & (US$ Million)

Table 47. Asia-Pacific Biologics for Tumors Market Size by Region (2026-2031) & (US$ Million)

Table 48. Latin America Biologics for Tumors Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 49. Latin America Biologics for Tumors Market Size by Country (2020-2025) & (US$ Million)

Table 50. Latin America Biologics for Tumors Market Size by Country (2026-2031) & (US$ Million)

Table 51. Middle East & Africa Biologics for Tumors Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 52. Middle East & Africa Biologics for Tumors Market Size by Country (2020-2025) & (US$ Million)

Table 53. Middle East & Africa Biologics for Tumors Market Size by Country (2026-2031) & (US$ Million)

Table 54. Roche Company Details

Table 55. Roche Business Overview

Table 56. Roche Biologics for Tumors Product

Table 57. Roche Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 58. Roche Recent Development

Table 59. Merck Company Details

Table 60. Merck Business Overview

Table 61. Merck Biologics for Tumors Product

Table 62. Merck Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 63. Merck Recent Development

Table 64. Novo Nordisk Company Details

Table 65. Novo Nordisk Business Overview

Table 66. Novo Nordisk Biologics for Tumors Product

Table 67. Novo Nordisk Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 68. Novo Nordisk Recent Development

Table 69. Sanofi Company Details

Table 70. Sanofi Business Overview

Table 71. Sanofi Biologics for Tumors Product

Table 72. Sanofi Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 73. Sanofi Recent Development

Table 74. Johnson & Johnson Company Details

Table 75. Johnson & Johnson Business Overview

Table 76. Johnson & Johnson Biologics for Tumors Product

Table 77. Johnson & Johnson Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 78. Johnson & Johnson Recent Development

Table 79. AbbVie Company Details

Table 80. AbbVie Business Overview

Table 81. AbbVie Biologics for Tumors Product

Table 82. AbbVie Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 83. AbbVie Recent Development

Table 84. Amgen Company Details

Table 85. Amgen Business Overview

Table 86. Amgen Biologics for Tumors Product

Table 87. Amgen Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 88. Amgen Recent Development

Table 89. AstraZeneca Company Details

Table 90. AstraZeneca Business Overview

Table 91. AstraZeneca Biologics for Tumors Product

Table 92. AstraZeneca Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 93. AstraZeneca Recent Development

Table 94. Takeda Pharmaceuticals Company Details

Table 95. Takeda Pharmaceuticals Business Overview

Table 96. Takeda Pharmaceuticals Biologics for Tumors Product

Table 97. Takeda Pharmaceuticals Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 98. Takeda Pharmaceuticals Recent Development

Table 99. Bristol-Myers Squib Company Details

Table 100. Bristol-Myers Squib Business Overview

Table 101. Bristol-Myers Squib Biologics for Tumors Product

Table 102. Bristol-Myers Squib Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 103. Bristol-Myers Squib Recent Development

Table 104. Pfizer Company Details

Table 105. Pfizer Business Overview

Table 106. Pfizer Biologics for Tumors Product

Table 107. Pfizer Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 108. Pfizer Recent Development

Table 109. Eli Lilly Company Details

Table 110. Eli Lilly Business Overview

Table 111. Eli Lilly Biologics for Tumors Product

Table 112. Eli Lilly Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 113. Eli Lilly Recent Development

Table 114. Novartis Company Details

Table 115. Novartis Business Overview

Table 116. Novartis Biologics for Tumors Product

Table 117. Novartis Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 118. Novartis Recent Development

Table 119. GSK Company Details

Table 120. GSK Business Overview

Table 121. GSK Biologics for Tumors Product

Table 122. GSK Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 123. GSK Recent Development

Table 124. CSL Limited Company Details

Table 125. CSL Limited Business Overview

Table 126. CSL Limited Biologics for Tumors Product

Table 127. CSL Limited Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 128. CSL Limited Recent Development

Table 129. Regeneron Pharmaceuticals Company Details

Table 130. Regeneron Pharmaceuticals Business Overview

Table 131. Regeneron Pharmaceuticals Biologics for Tumors Product

Table 132. Regeneron Pharmaceuticals Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 133. Regeneron Pharmaceuticals Recent Development

Table 134. Kexing Biopharm Company Details

Table 135. Kexing Biopharm Business Overview

Table 136. Kexing Biopharm Biologics for Tumors Product

Table 137. Kexing Biopharm Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 138. Kexing Biopharm Recent Development

Table 139. Biogen Company Details

Table 140. Biogen Business Overview

Table 141. Biogen Biologics for Tumors Product

Table 142. Biogen Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 143. Biogen Recent Development

Table 144. GileadSciences Company Details

Table 145. GileadSciences Business Overview

Table 146. GileadSciences Biologics for Tumors Product

Table 147. GileadSciences Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 148. GileadSciences Recent Development

Table 149. Shanghai Junshi Biosciences Company Details

Table 150. Shanghai Junshi Biosciences Business Overview

Table 151. Shanghai Junshi Biosciences Biologics for Tumors Product

Table 152. Shanghai Junshi Biosciences Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 153. Shanghai Junshi Biosciences Recent Development

Table 154. Sarepta Therapeutics, Inc. Company Details

Table 155. Sarepta Therapeutics, Inc. Business Overview

Table 156. Sarepta Therapeutics, Inc. Biologics for Tumors Product

Table 157. Sarepta Therapeutics, Inc. Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 158. Sarepta Therapeutics, Inc. Recent Development

Table 159. Changchun High-Tech Industry Company Details

Table 160. Changchun High-Tech Industry Business Overview

Table 161. Changchun High-Tech Industry Biologics for Tumors Product

Table 162. Changchun High-Tech Industry Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 163. Changchun High-Tech Industry Recent Development

Table 164. Sino Biopharmaceutical Limited Company Details

Table 165. Sino Biopharmaceutical Limited Business Overview

Table 166. Sino Biopharmaceutical Limited Biologics for Tumors Product

Table 167. Sino Biopharmaceutical Limited Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 168. Sino Biopharmaceutical Limited Recent Development

Table 169. Kexing Biopharm Company Details

Table 170. Kexing Biopharm Business Overview

Table 171. Kexing Biopharm Biologics for Tumors Product

Table 172. Kexing Biopharm Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 173. Kexing Biopharm Recent Development

Table 174. 3SBio Inc. Company Details

Table 175. 3SBio Inc. Business Overview

Table 176. 3SBio Inc. Biologics for Tumors Product

Table 177. 3SBio Inc. Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 178. 3SBio Inc. Recent Development

Table 179. CARsgen Company Details

Table 180. CARsgen Business Overview

Table 181. CARsgen Biologics for Tumors Product

Table 182. CARsgen Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 183. CARsgen Recent Development

Table 184. Innovent Biologics Company Details

Table 185. Innovent Biologics Business Overview

Table 186. Innovent Biologics Biologics for Tumors Product

Table 187. Innovent Biologics Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 188. Innovent Biologics Recent Development

Table 189. Qilu Pharmaceutical Company Details

Table 190. Qilu Pharmaceutical Business Overview

Table 191. Qilu Pharmaceutical Biologics for Tumors Product

Table 192. Qilu Pharmaceutical Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 193. Qilu Pharmaceutical Recent Development

Table 194. Boehringer Ingelheim Company Details

Table 195. Boehringer Ingelheim Business Overview

Table 196. Boehringer Ingelheim Biologics for Tumors Product

Table 197. Boehringer Ingelheim Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 198. Boehringer Ingelheim Recent Development

Table 199. BeiGene Company Details

Table 200. BeiGene Business Overview

Table 201. BeiGene Biologics for Tumors Product

Table 202. BeiGene Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 203. BeiGene Recent Development

Table 204. Jiangsu Hengrui Pharmaceuticals Company Details

Table 205. Jiangsu Hengrui Pharmaceuticals Business Overview

Table 206. Jiangsu Hengrui Pharmaceuticals Biologics for Tumors Product

Table 207. Jiangsu Hengrui Pharmaceuticals Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 208. Jiangsu Hengrui Pharmaceuticals Recent Development

Table 209. Alphamab Oncology Company Details

Table 210. Alphamab Oncology Business Overview

Table 211. Alphamab Oncology Biologics for Tumors Product

Table 212. Alphamab Oncology Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 213. Alphamab Oncology Recent Development

Table 214. Shanghai Henlius Biotech Company Details

Table 215. Shanghai Henlius Biotech Business Overview

Table 216. Shanghai Henlius Biotech Biologics for Tumors Product

Table 217. Shanghai Henlius Biotech Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 218. Shanghai Henlius Biotech Recent Development

Table 219. Ionis Pharmaceuticals Company Details

Table 220. Ionis Pharmaceuticals Business Overview

Table 221. Ionis Pharmaceuticals Biologics for Tumors Product

Table 222. Ionis Pharmaceuticals Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 223. Ionis Pharmaceuticals Recent Development

Table 224. Gan & Lee Pharmaceuticals Company Details

Table 225. Gan & Lee Pharmaceuticals Business Overview

Table 226. Gan & Lee Pharmaceuticals Biologics for Tumors Product

Table 227. Gan & Lee Pharmaceuticals Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 228. Gan & Lee Pharmaceuticals Recent Development

Table 229. Anhui Anke Biotechnology Company Details

Table 230. Anhui Anke Biotechnology Business Overview

Table 231. Anhui Anke Biotechnology Biologics for Tumors Product

Table 232. Anhui Anke Biotechnology Revenue in Biologics for Tumors Business (2020-2025) & (US$ Million)

Table 233. Anhui Anke Biotechnology Recent Development

Table 234. Research Programs/Design for This Report

Table 235. Key Data Information from Secondary Sources

Table 236. Key Data Information from Primary Sources

Table 237. Authors List of This Report

List of Figures

Figure 1. Biologics for Tumors Picture

Figure 2. Global Biologics for Tumors Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Biologics for Tumors Market Share by Type: 2024 VS 2031

Figure 4. Monoclonal Antibodies Features

Figure 5. Recombinant Protein Drugs Features

Figure 6. Antibody-Drug Conjugates (ADCs) Features

Figure 7. Enzyme Replacement Therapy Features

Figure 8. CAR-T Drugs Features

Figure 9. Small Nucleic Acid Drugs Features

Figure 10. Others Features

Figure 11. Global Biologics for Tumors Market Size Comparison by Properties (2020-2031) & (US$ Million)

Figure 12. Biopharmaceuticals Features

Figure 13. Biosimilars Features

Figure 14. Global Biologics for Tumors Market Size by Application (2020-2031) & (US$ Million)

Figure 15. Global Biologics for Tumors Market Share by Application: 2024 VS 2031

Figure 16. Lymphoma Case Studies

Figure 17. Myeloma Case Studies

Figure 18. Colorectal Case Studies

Figure 19. Renal Cell Carcinoma Case Studies

Figure 20. Others Case Studies

Figure 21. Biologics for Tumors Report Years Considered

Figure 22. Global Biologics for Tumors Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 23. Global Biologics for Tumors Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 24. Global Biologics for Tumors Market Share by Region: 2024 VS 2031

Figure 25. Global Biologics for Tumors Market Share by Players in 2024

Figure 26. Global Biologics for Tumors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 27. The Top 10 and 5 Players Market Share by Biologics for Tumors Revenue in 2024

Figure 28. North America Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. North America Biologics for Tumors Market Share by Country (2020-2031)

Figure 30. United States Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Canada Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 32. Europe Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Europe Biologics for Tumors Market Share by Country (2020-2031)

Figure 34. Germany Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. France Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. U.K. Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Italy Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Russia Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Ireland Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 40. Asia-Pacific Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Asia-Pacific Biologics for Tumors Market Share by Region (2020-2031)

Figure 42. China Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Japan Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 44. South Korea Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Southeast Asia Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. India Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Australia & New Zealand Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 48. Latin America Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 49. Latin America Biologics for Tumors Market Share by Country (2020-2031)

Figure 50. Mexico Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 51. Brazil Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 52. Middle East & Africa Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 53. Middle East & Africa Biologics for Tumors Market Share by Country (2020-2031)

Figure 54. Israel Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 55. Saudi Arabia Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 56. UAE Biologics for Tumors Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 57. Roche Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 58. Merck Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 59. Novo Nordisk Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 60. Sanofi Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 61. Johnson & Johnson Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 62. AbbVie Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 63. Amgen Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 64. AstraZeneca Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 65. Takeda Pharmaceuticals Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 66. Bristol-Myers Squib Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 67. Pfizer Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 68. Eli Lilly Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 69. Novartis Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 70. GSK Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 71. CSL Limited Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 72. Regeneron Pharmaceuticals Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 73. Kexing Biopharm Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 74. Biogen Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 75. GileadSciences Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 76. Shanghai Junshi Biosciences Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 77. Sarepta Therapeutics, Inc. Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 78. Changchun High-Tech Industry Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 79. Sino Biopharmaceutical Limited Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 80. Kexing Biopharm Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 81. 3SBio Inc. Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 82. CARsgen Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 83. Innovent Biologics Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 84. Qilu Pharmaceutical Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 85. Boehringer Ingelheim Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 86. BeiGene Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 87. Jiangsu Hengrui Pharmaceuticals Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 88. Alphamab Oncology Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 89. Shanghai Henlius Biotech Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 90. Ionis Pharmaceuticals Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 91. Gan & Lee Pharmaceuticals Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 92. Anhui Anke Biotechnology Revenue Growth Rate in Biologics for Tumors Business (2020-2025)

Figure 93. Bottom-up and Top-down Approaches for This Report

Figure 94. Data Triangulation

Figure 95. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Biologics for Tumors Market Research Report 2025

Published Date: November 2025

Report Code: QYRE-Auto-30B19750

Global Biologics for Tumors Market Research Report 2025

FEATURED COMPANIES

Biologics for Tumors Market Size

Biologics for Tumors Market

Scope of Biologics for Tumors Market Report

Chapter Outline

FAQ for this report

How fast is Biologics for Tumors Market growing?

What is the Biologics for Tumors Market size in 2031?

Who are the main players in the Biologics for Tumors Market report?

What are the Application segmentation covered in the Biologics for Tumors Market report?

What are the Type segmentation covered in the Biologics for Tumors Market report?

FEATURED COMPANIES